Try our mobile app

Supernus to Participate in Upcoming November Investor Conferences

Published: 2021-11-10 21:05:00 ET
<<<  go to SUPN company page

ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will participate and host investor meetings at the following upcoming November 2021 investor conferences.

Stifel 2021 Virtual Healthcare ConferenceDate: November 15, 2021Participation Type: Fireside ChatPresentation Time: 2:00 p.m. EST

Jefferies London Healthcare ConferenceDate: November 18, 2021Participation Type: Fireside ChatPresentation Time: Pre-recorded, available beginning November 18 at 3:00 a.m. EST / 8:00 a.m. GMT

A live webcast of the Stifel fireside chat, as well as replays of both fireside chats will be accessible by visiting Events & Presentations in the Investor section on the Company's website at www.supernus.com. An archived replay of each webcast will be available for 60 days on the Company's website after the respective conference.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.

For more information, please visit www.supernus.com.

CONTACTS:

Jack A. Khattar, President and CEOTimothy C. Dec, Senior Vice President and CFO Supernus Pharmaceuticals, Inc.Tel: (301) 838-2591

or

INVESTOR CONTACT:Peter VozzoICR WestwickeOffice: (443) 213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com

Primary Logo

Source: Supernus Pharmaceuticals, Inc.